Sometimes I listen to a PBS or NPR stream in the background while running our end–of-month mediaQuant refresh. There’s a considerable amount of monitoring as our massive data crawl moves across the media landscape.

I was lucky to catch the recent PBS special on cancer based upon the Pulitzer Prize winning book, The Emperor of All Maladies by Siddhartha Mukherjee, along with the amazing film adaptation by Barak Goodman and his team.

It’s definitely an emotional roller-coaster.  Be prepared.

As the series concluded, I couldn’t help but delve into April’s media numbers as they began their final aggregation steps on our servers, with a quick look into immunotherapy (up +1 point or 2 percent at 63) and related trends, and pharma brands.

Seeing the groundbreaking and life-saving work these researchers and doctors are doing puts media measurement in some perspective. I’m just so glad there are people who have made this their passion. The clever adaptation of our own immune system to help combat the most serious threat to our health just leaves me awestruck.

We’re tracking all the major pharma companies along with hundreds of current and in-trial drugs that address all types of maladies – with quite a focus on cancer specific drugs.

The PBS series ended on a very hopeful note – immunotherapy – a topic we’ve been tracking in the media for nearly 4-years.  The specific immunotherapy drugs being developed are typically classified as PD-1 or PD-L1 inhibitors (+3 points or 7 percent at 43).

Much of the cancer media coverage affecting current ratings has focused on various efforts to develop this new class of cancer drug.

Firms like Merck (off -2 points at 78) have nearly 35 clinical trials underway in the PD-1 inhibitor area alone.  And analyst suggest the market will quickly grow to $35 billion annually.

One science/medical trend that is getting less attention is still promising treatment approach referred to as targeted therapies (up +2 points or 3 percent at 55).   Announcements from the White House indicating renewed investments in targeted therapies drove media rating spikes in 2014, but the media has quickly shifted its focus to Merck, Bristol-Myers Squibb (+1 point at 69) and other pharma companies who have greatly expanded their R&D and media efforts on immunotherapy.

 

 

 

 

 

We’re continuing our media measurement in this emerging field as the key brand players work through dozens of clinical trials and FDA drug reviews.  2015 is shaping up to be an amazing year in the drug delivery market, and not all too soon given the urgency underlying the emperor of all maladies.

Our media coverage is extensive in this area, from our recent Conditions and Disease Trends report to our  Pharmaceutical Drug Brands media coverage.  Also, subscribe to our data dashboards for complete and focused access to these and more trends, brands and influencer media rating metrics.

Paul